Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlobalData Plc    DATA   GB00B87ZTG26

GLOBALDATA PLC

(DATA)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

GlobalData : Personalized medicines may improve identification of optimal treatment but access to these treatments may be difficult, says GlobalData

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/07/2019 | 04:35am EST
07 Nov 2019
Personalized medicines may improve identification of optimal treatment but access to these treatments may be difficult, says GlobalData
Posted in Pharma

'Personalized medicine' and 'precision medicine' are both defined as using a patient's genomic and phenotypic data to find targeted therapies. These therapies use a proactive approach, increase patient stratification and targeting, and aim to improve outcomes for healthcare players, according to GlobalData, a leading data and analytics company.

GlobalData's latest thematic report, 'The State of Personalized/Precision Medicine', suggests that the key benefit of personalized and precision medicines is improved selection of an optimal treatment path, benefitting both patients and payers, as potentially ineffective medicines will be less likely to see use in specific patient pools.

Michael Breen, PhD, Associate Director at GlobalData, comments: 'When a disease has different patient segments, it's possible that not all will respond to a particular medicine the same way, if at all. By identifying patient subgroups through biomarker analysis, personalized medicine will help identify which groups may benefit from a given treatment. This helps the patient get the most appropriate treatment more quickly, saving money for the payer since they are less likely to reimburse ineffective therapeutics.'

The majority of attention for personalized medicine has been in oncology, but there is an unmet need for expansion to other indications.

Fern Barkalow, PhD, Senior Director at GlobalData reports: 'While Oncology has led the way in terms of precision medicine development, these therapies are positioned to fulfil unmet needs in other therapeutic areas.

'Approximately 90% of the top-marketed precision medicine therapies in 2018 were approved for oncology indications, and these can serve as a roadmap for development of precision medicine drugs in other therapeutic areas. The report highlights a variety of case studies in oncology that should be useful to many stakeholders pursuing this approach.'

Development costs associated with personalized therapies are expected to be higher than average, partially due to the highly specific nature of these agents, coupled with the need for a companion diagnostic. Accordingly, experts report that the greatest challenge with development and launch of these therapies relate to market access hurdles.

Breen concludes: 'Due to trials being inherently more complex and expensive to conduct for personalized medicines, these costs ultimately are passed down to the end user, resulting in these drugs being priced at a premium, and likely being more intensely scrutinized at the level of reimbursement.'

Disclaimer

GlobalData plc published this content on 07 November 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 November 2019 09:34:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLOBALDATA PLC
01:16aGLOBALDATA : Asia set to drive global acetone capacity additions by 2023, says G..
PU
11/20GLOBALDATA : US signs the highest long-term LNG export contract volumes globally..
PU
11/20Retailers Split on Outlook for Holiday Sales -- WSJ
DJ
11/19Retailer Results Send Mixed Signals on Consumer Spending
DJ
11/13GLOBALDATA : China houses five of top ten mega capacity coal power plants global..
PU
11/12GLOBALDATA : Citi leads GlobalData's top 10 global M&A financial advisers league..
PU
11/12GLOBALDATA : Haynesville Shale expected to play crucial role in meeting future n..
PU
11/12GLOBALDATA : Europe's tourism & leisure industry sees a rise of 5.05% in deal ac..
AQ
11/12GLOBALDATA : Citi tops GlobalData's top 10 global M&A financial advisers league ..
AQ
11/12GLOBALDATA : North America remains epicenter of global VC funding activity durin..
AQ
More news
Financials (GBP)
Sales 2019 177 M
EBIT 2019 40,1 M
Net income 2019 15,0 M
Debt 2019 50,1 M
Yield 2019 1,26%
P/E ratio 2019 95,1x
P/E ratio 2020 59,7x
EV / Sales2019 7,45x
EV / Sales2020 6,97x
Capitalization 1 268 M
Chart GLOBALDATA PLC
Duration : Period :
GlobalData Plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLOBALDATA PLC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 2
Average target price 920,00  GBp
Last Close Price 1 075,00  GBp
Spread / Highest target -14,4%
Spread / Average Target -14,4%
Spread / Lowest Target -14,4%
EPS Revisions
Managers
NameTitle
Michael Thomas Danson Chief Executive Officer & Director
Bernard Anthony Cragg Chairman
Graham Charles Lilley Chief Financial Officer, Secretary & Director
Peter Martin Harkness Independent Non-Executive Director
Murray Legg Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
GLOBALDATA PLC82.98%1 638
S&P GLOBAL INC.57.63%65 467
RELX14.14%46 787
THOMSON REUTERS CORPORATION43.97%35 876
WOLTERS KLUWER24.43%19 310
EQUIFAX INC.51.77%17 114